Methods and compositions for the treatment of CNS-related conditions
View Patent ↗The present invention provides novel methods and compositions for the treatment and prevention of CNS-related conditions. One of the CNS-related conditions treated by the methods and compositions of the invention is Alzheimer's disease.
1. A method of treating a CNS-related condition comprising orally administering once a day to a human subject in need thereof:
(a) 5-40 mg memantine or a pharmaceutically acceptable salt thereof provided in an extended release dosage form, wherein said extended release memantine or pharmaceutically acceptable salt thereof provides a change in plasma concentration as a function of time (dC/dT) that is less than about 50% of the dC/dT of the same quantity of an immediate release form of memantine, wherein the dC/dT is measured in a single dose human PK study between the time period of 0 to Tmax of the immediate release form of memantine; and
(b) a therapeutically effective amount of donepezil or a pharmaceutically acceptable salt thereof, wherein the CNS-related condition is selected from the group consisting of Alzheimer's disease and dementia.
2. The method of claim 1 , wherein the amount of memantine or pharmaceutically acceptable salt thereof ranges between 10 to 40 mg per dose.
3. The method of claim 2 , wherein the amount of memantine or pharmaceutically acceptable salt thereof ranges between 12.5 to 40 mg per dose.
4. The method of claim 1 , wherein said memantine or a pharmaceutically acceptable salt thereof and said donepezil or a pharmaceutically acceptable salt thereof are administered simultaneously.
5. The method of claim 1 , wherein said memantine or a pharmaceutically acceptable salt thereof and said donepezil or a pharmaceutically acceptable salt thereof are administered as a single composition.
6. A method of reducing the potential for an adverse effect in a human subject being treated for a CNS-related condition comprising orally administering once a day to a human subject in need thereof a pharmaceutical composition comprising:
(a) 5-40 mg memantine or a pharmaceutically acceptable salt thereof in an extended release form, wherein said extended release memantine or pharmaceutically acceptable salt thereof provides a change in plasma concentration as a function of time (dC/dT) that is less than about 50% of the dC/dT of the same quantity of an immediate release form of memantine, wherein the dC/dT is measured in a single dose human PK study between the time period of 0 to Tmax of the immediate release form of memantine; and
(b) donepezil or a pharmaceutically acceptable salts thereof, wherein the CNS-related condition is selected from the group consisting of Alzheimer's disease and dementia;
and further wherein said adverse effect is related to memantine.
7. The method of claim 6 , wherein the composition is in a unit dosage form comprising 10 to 40 mg of the memantine or pharmaceutically acceptable salt thereof.
8. The method of claim 6 , wherein the donepezil or pharmaceutically acceptable salt thereof is in an immediate release form.
9. The method of claim 6 , wherein the memantine or pharmaceutically acceptable salt thereof is formulated as beads and/or pellets.
10. The method of claim 9 , wherein the beads and/or pellets comprise an extended release coating.
11. The method of claim 10 , wherein the extended release coating comprises an insoluble matrix polymer and a water soluble material.
12. The method of claim 11 , wherein the insoluble matrix polymer is ethyl cellulose.
13. The method of claim 11 , wherein the insoluble matrix polymer is ethyl cellulose, and the water soluble material is selected from the group consisting of hydroxypropyl methyl cellulose and polyvinylpyrrolidone.
14. The method of claim 7 , wherein the dosage form is in a capsule.
15. The method of claim 6 , wherein the composition comprises 1 to 20 mg donepezil hydrochloride.
16. The method of claim 6 , wherein administration of the composition to a human subject provides a shift in memantine T max of at least 8 hours relative to an immediate release form of memantine.
17. The method of claim 6 , wherein administration of the composition to a human subject provides a memantine T max of at least 19 hours.
18. The method of claim 6 , wherein administration of the composition to a human subject provides a plasma memantine concentration profile characterized by a maximum memantine plasma concentration to mean memantine plasma concentration ratio (Cmax/cmean) of about 2.5 to 2 at 1 hour to at least 6 hours after administration.
19. The method of claim 6 , wherein said memantine or a pharmaceutically acceptable salt thereof and said donepezil or a pharmaceutically acceptable salt thereof are provided in a unit dosage form.
20. The method of claim 6 , wherein the composition comprises at 12.5 mg to 40 mg memantine hydrochloride.
21. The method of claim 6 , wherein the composition comprises at least 22.5 mg memantine hydrochloride and 1 to 20 mg of donepezil hydrochloride.
22. The method of claim 1 , wherein said extended release memantine or a pharmaceutically acceptable salt thereof has an in vitro dissolution profile less than 30% in one hour, less than 40% in two hours, greater than 40% in six hours as measured using a USP type 2 (paddle) dissolution system at 50 rpm, at a temperature of 37±0.5° with water as a dissolution medium.
23. The method of claim 1 , wherein at least 80% of the memantine or pharmaceutically acceptable salt thereof in the composition is provided in an extended release form, with the remainder in an immediate release form.
24. The method of claim 1 , wherein at least 95% of the memantine or pharmaceutically acceptable salt thereof in the composition is provided in an extended release forms, with the remainder in an immediate release form.
25. The method of claim 1 , wherein the release of the memantine or pharmaceutically acceptable salt thereof is monophasic.
26. The method of claim 1 , wherein the release of the memantine or pharmaceutically acceptable salt thereof is biphasic.
27. The method of claim 1 , wherein the memantine further comprises one or more extended release excipients selected from the group consisting of ethyl cellulose, hydroxypropyl methyl cellulose and polyvinylpyrrolidone.
28. The method of claim 6 , wherein the composition comprises 20 mg to 40 mg of memantine.
29. The method of claim 6 , wherein at least 80% of the memantine or pharmaceutically acceptable salt thereof in the composition is provided in an extended release form, with the remainder in an immediate release form.
30. The method of claim 6 , wherein at least 95% of the memantine or pharmaceutically acceptable salt thereof in the composition is provided in an extended release forms, with the remainder in an immediate release form.
31. The method of claim 6 , wherein the release of the memantine or pharmaceutically acceptable salt thereof is monophasic.
32. The method of claim 6 , wherein the release of the memantine or pharmaceutically acceptable salt thereof is biphasic.
33. The method of claim 6 , wherein the memantine further comprises one or more extended release excipients selected from the group consisting of ethyl cellulose, hydroxypropyl methyl cellulose and polyvinylpyrrolidone.
34. In a method of treating a subject for a CNS-related condition comprising administering to said subject a memantine drug selected from the group consisting of memantine and a pharmaceutically acceptable salt thereof, and a therapeutically effective amount of a donepezil drug selected from the group consisting of donepezil and a pharmaceutically acceptable salt thereof, the improvement comprising:
(a) said memantine drug is administered in an extended release dosage form, wherein said extended release memantine provides a change in plasma concentration as a function of time (dC/dT) in a defined time period of 0 to Tmax of an immediate release form of memantine after administration, as measured in a human single dose PK study, that is less than about 50% of the change in plasma concentration (dC/dT) of the same quantity of said immediate release form of said memantine drug during said defined time period; and
(b) said memantine drug is administered once daily in a dose range of 5 mg to 40 mg; wherein said CNS-related condition is selected from the group consisting of Alzheimer's disease and Parkinson's disease.
35. The method of claim 34 , wherein said memantine drug daily dose range is 10 mg to 40 mg.
36. The method of claim 34 , wherein said memantine drug and said donepezil drug are administered as a composition.
37. The method of claim 35 , wherein said memantine drug and said donepezil drug are administered in a unit dosage form.
38. The method of claim 36 , wherein said donepezil drug is administered in an immediate release form.
39. The method of claim 37 , wherein said donepezil drug is administered in an immediate release form.
40. The method of claim 1 , wherein the amount of said memantine or pharmaceutically acceptable salt thereof ranges between 20 to 40 mg per dose.
41. The method of claim 5 , wherein the amount of said memantine or pharmaceutically acceptable salt thereof ranges between 12.5 to 40 mg per dose.
42. The method of claim 6 , wherein the amount of said memantine or pharmaceutically acceptable salt thereof ranges between 10 to 40 mg per dose.
43. The method of claim 40 , wherein said memantine or pharmaceutically acceptable salt thereof and said donepezil or a pharmaceutically acceptable salt thereof are administered in a unit dosage form.
44. The method of claim 42 , wherein said memantine or pharmaceutically acceptable salt thereof and said donepezil or a pharmaceutically acceptable salt thereof are administered in a unit dosage form.
45. The method of claim 41 , wherein said donepezil or a pharmaceutically acceptable salt thereof is administered in an immediate release form.
46. The method of claim 43 , wherein said donepezil or a pharmaceutically acceptable salt thereof is administered in an immediate release form.
47. The method of claim 41 , wherein said donepezil or a pharmaceutically acceptable salt thereof is administered in an immediate release form.
48. The method of claim 1 , wherein the amount of said memantine or pharmaceutically acceptable salt thereof ranges between 22.5 mg to 40 mg per dose.
49. The method of claim 6 , wherein the amount of said memantine or pharmaceutically acceptable salt thereof ranges between 22.5 mg to 40 mg per dose.
50. The method of claim 34 , wherein the amount of said memantine or pharmaceutically acceptable salt thereof ranges between 12.5 mg to 40 mg per dose.
51. The method of claim 34 , wherein the amount of said memantine or pharmaceutically acceptable salt thereof ranges between 20 mg to 40 mg per dose.
52. The method of claim 34 , wherein the amount of said memantine or pharmaceutically acceptable salt thereof ranges between 22.5 mg to 40 mg per dose.
53. The method of claim 1 , wherein the defined time period of 0 to Tmax of an immediate release form of memantine is the first 6 hours after administration.
54. The method of claim 6 , wherein the defined time period of 0 to Tmax of an immediate release form of memantine is the first 6 hours after administration.
55. The method of claim 34 , wherein the defined time period of 0 to Tmax of an immediate release form of memantine is the first 6 hours after administration.
56. The method of claim 48 , wherein the defined time period of 0 to Tmax of an immediate release form of memantine is the first 6 hours after administration.
57. The method of claim 49 , wherein the defined time period of 0 to Tmax of an immediate release form of memantine is the first 6 hours after administration.
58. The method of claim 52 , wherein the defined time period of 0 to Tmax of an immediate release form of memantine is the first 6 hours after administration.